As previously reported by HFA and NHF, Takeda announced the recall of two lots of VONVENDI von Willebrand factor (recombinant) 1,300 I.U. vials on February 25, 2020. HFA and NHF recognize that recalls can be very unsettling for many in the bleeding disorders community. On February 27, 2020, the patient organizations announced that they had submitted a letter to Takeda with follow-up questions regarding the pharmacy-level VONVENDI recall. Takeda responded to the HFA-NHF letter late yesterday; you can read Takeda’s responses here.
HFA and NHF will continue to keep the bleeding disorders community informed as any further information is gathered.
Please note that NHF and HFA do not recommend, endorse or make any representation about the efficacy, appropriateness or suitability of any specific products, treatments, or opinions. If you have any questions or concerns about your medical treatment, including your possible exposure to recalled product, please consult your physician.